Physician profile
Larry G Burrows
NPI 1669402533
$3,228.45
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $283 · 2021: $1,037 · 2022: $741.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $412.07 | 2019-2022 | |
| Novo Nordisk INC | $371.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.50 | 2019-2022 | |
| Glaxosmithkline, LLC. | $282.10 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $196.31 | 2019-2022 | |
| Pfizer INC. | $181.76 | 2019-2021 | |
| Abbvie INC. | $162.57 | 2021-2022 | |
| Amarin Pharma, INC. | $150.11 | 2019-2022 | |
| Amgen INC. | $89.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $85.57 | 2019-2021 | |
| Abbott Laboratories | $84.52 | 2021 | |
| Lilly USA, LLC | $84.33 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.46 | 2021-2022 | |
| Allergan, INC. | $82.81 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $76.89 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $74.35 | 2019-2021 | |
| Mylan Specialty L.P. | $53.59 | 2019-2021 | |
| Nevro Corp. | $53.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.90 | 2019-2021 | |
| Dexcom, INC. | $51.13 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.45 | 2019-2022 | |
| Genentech USA, INC. | $43.66 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.06 | 2022 | |
| Merck Sharp & Dohme LLC | $35.16 | 2019 | |
| Mdd US Operations, LLC | $31.65 | 2019-2020 | |
| Ucb, INC. | $24.97 | 2019 | |
| Shire North American Group INC | $19.44 | 2019 | |
| Eisai INC. | $19.04 | 2022 | |
| Lundbeck LLC | $15.89 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.99 | 2022 | |
| Astellas Pharma US INC | $12.58 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.27 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.